Puma Biotechnology
PBYI
133 hedge funds and large institutions have $274M invested in Puma Biotechnology in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 57 increasing their positions, 36 reducing their positions, and 27 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 36
10% more call options, than puts
Call options by funds: $6.83M | Put options by funds: $6.21M
8% less funds holding
Funds holding: 144 → 133 (-11)
13.54% less ownership
Funds ownership: 94% → 80.46% (-14%)
30% less capital invested
Capital invested by funds: $394M → $274M (-$119M)
33% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 27
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$9.71M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.48M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.06M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.78M |
| 5 |
DM
Deerfield Management
New York
|
+$3.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$39.7M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$15.3M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$8.8M |
| 4 |
O
OrbiMed
New York
|
-$6.85M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$6.32M |
PBYI Hedge Fund Activity: Q4 2019 in Review
133 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2019, worth a combined $274M — down 30% from $394M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of PBYI and 18 opened new positions — a net loss of 9 holders — while 36 trimmed existing stakes and 57 added.
The largest buyer was Millennium Management, adding an estimated $9.71M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $39.7M sold.
- 133 institutional investors held Puma Biotechnology (PBYI) as of Q4 2019, down from 144 in Q3 2019.
- Funds reported $274M of Puma Biotechnology stock for Q4 2019, down 30% quarter-over-quarter.
- 18 funds opened new Puma Biotechnology positions in Q4 2019 and 27 closed out, a net change of -9 holders.
- The largest Puma Biotechnology buyer in Q4 2019 was Millennium Management, an estimated $9.71M added.
- The largest Puma Biotechnology seller in Q4 2019 was PFM Health Sciences, an estimated $39.7M sold.
Based on aggregated 13F filings for Q4 2019.